Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973400 | 1.00 | GRIK1 (0.36) | GRIK1GRIK2CYP2C19CPA1SMN1; SMN2 | |
| SCHEMBL466127 | 0.81 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL7164140 | 0.81 | GRIK1 (0.39) | GRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL2981714 | 0.79 | MEN1 (0.36) | — | |
| SCHEMBL2981716 | 0.79 | MEN1 (0.36) | — | |
| Ammonia Solution, Strong SCHEMBL27395046 | 0.79 | GRIK1 (0.38) | GRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL1583283 | 0.76 | GRIK1 (0.36) | GRIK1GRIK2CYP2C19CPA1SMN1; SMN2 | |
| SCHEMBL2968992 | 0.75 | AAK1 (0.36) | GRIK1GRIK2CYP2C19CPA1 | |
| SCHEMBL2980668 | 0.75 | CHRM1 (0.42) | GRIK1GRIK2CYP2C19CPA1CHRM1 | |
| SCHEMBL2979584 | 0.75 | ALDH1A1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576588-A1 | METHODS FOR THE SYNTHESIS OF ALKYNE-CONTAINING DICARBA BRIDGES IN PEPTIDES | Syngene Limited (AU) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011146974-A1 | METHODS FOR THE SYNTHESIS OF ALKYNE-CONTAINING DICARBA BRIDGES IN PEPTIDES | MONASH UNIVERSITY (AU) | 2011-12-01 | — | — | WO | disclosed |
| US-7772221-B2 | Diaminopropane derived macrocycles as inhibitors of β amyloid production | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080194535-A1 | DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194535-A1 | DIAMINOPROPANE DERIVED MACROCYCLES AS INHIBITORS OF BETA AMYLOID PRODUCTION | APP, BACE1, BACE2 | GRIK1 828/4885GRIK2 929/4885CYP2C19 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.